NI200800290A - Moduladores bencimidazólicos de vr1 - Google Patents

Moduladores bencimidazólicos de vr1

Info

Publication number
NI200800290A
NI200800290A NI200800290A NI200800290A NI200800290A NI 200800290 A NI200800290 A NI 200800290A NI 200800290 A NI200800290 A NI 200800290A NI 200800290 A NI200800290 A NI 200800290A NI 200800290 A NI200800290 A NI 200800290A
Authority
NI
Nicaragua
Prior art keywords
benzymidazolic
modulators
compounds
formula
treatment
Prior art date
Application number
NI200800290A
Other languages
English (en)
Inventor
R Player Mark
L Dax Scott
H Parsons William
Brandt Michael
R Calvo Raul
Patel Sharmila
Liu Jian
S Cheung Wing
C Jetter Michele
Lee Yu-Kai
A Youngman Mark
Pan Wenxi
M Wells Kenneth
A Beauchamp Derek
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI200800290A publication Critical patent/NI200800290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La invención se refiere a compuestos de Fórmula (I): a composiciones farmacéuticas que contienen tales compuestos y a métodos de tratamiento para utilizarlos.
NI200800290A 2006-05-03 2008-11-03 Moduladores bencimidazólicos de vr1 NI200800290A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03

Publications (1)

Publication Number Publication Date
NI200800290A true NI200800290A (es) 2012-01-30

Family

ID=38566108

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200800290A NI200800290A (es) 2006-05-03 2008-11-03 Moduladores bencimidazólicos de vr1

Country Status (37)

Country Link
US (3) US7951829B2 (es)
EP (1) EP2021330B1 (es)
JP (1) JP5302884B2 (es)
KR (1) KR101434883B1 (es)
CN (1) CN101511797B (es)
AR (1) AR060840A1 (es)
AT (1) ATE482201T1 (es)
AU (1) AU2007248341C1 (es)
BR (1) BRPI0709803B8 (es)
CA (1) CA2651128C (es)
CO (1) CO6160329A2 (es)
CR (1) CR10479A (es)
CY (1) CY1111269T1 (es)
DE (1) DE602007009378D1 (es)
DK (1) DK2021330T3 (es)
EA (1) EA019386B1 (es)
EC (1) ECSP088854A (es)
ES (1) ES2350959T3 (es)
HK (1) HK1131971A1 (es)
HR (1) HRP20100700T1 (es)
IL (1) IL194916A (es)
JO (1) JO3602B1 (es)
MX (1) MX2008014108A (es)
MY (1) MY154595A (es)
NI (1) NI200800290A (es)
NO (1) NO341965B1 (es)
NZ (1) NZ572251A (es)
PE (1) PE20080065A1 (es)
PL (1) PL2021330T3 (es)
PT (1) PT2021330E (es)
RS (1) RS51473B (es)
SI (1) SI2021330T1 (es)
TW (1) TWI419882B (es)
UA (1) UA94749C2 (es)
UY (1) UY30322A1 (es)
WO (1) WO2007130780A2 (es)
ZA (1) ZA200810234B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333990A1 (en) * 2006-12-15 2008-06-26 Janssen Pharmaceutica N.V. Benzimidazole TRPV1 inhibitors
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US20090156598A1 (en) * 2007-12-17 2009-06-18 Lebsack Alec D Imidazolopyrimidine modulators of TRPV1
WO2009078999A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
ES2539290T3 (es) * 2008-04-18 2015-06-29 Daewoong Pharmaceutical Co., Ltd. Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 双噁唑啉基烷烃化合物的精制方法
DK2709619T3 (en) 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
US9895330B2 (en) 2013-07-11 2018-02-20 Bristol-Myers Squibb Company IDO inhibitors
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
EP3348554B1 (en) * 2015-09-08 2020-05-06 Sumitomo Chemical Company, Limited Method for producing triazole compound
JP7041141B2 (ja) * 2016-11-01 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
MX2020011405A (es) * 2018-05-03 2021-01-08 Jiangsu Hengrui Medicine Co Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
CN108997398B (zh) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
TW202118751A (zh) * 2019-10-31 2021-05-16 大陸商江蘇恒瑞醫藥股份有限公司 RORγ調節劑的酸加成鹽
WO2021248008A1 (en) 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
CA2501539A1 (en) * 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
BRPI0413072A (pt) * 2003-07-28 2006-10-03 Janssen Pharmaceutica Nv moduladores de lta4h
AU2004285053B2 (en) * 2003-10-28 2010-10-21 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
MX2009000149A (es) * 2006-07-04 2009-01-23 Janssen Pharmaceutica Nv Agonistas de bencimidazol canabinoide que portan un grupo heterociclico sustituido.
AU2007333990A1 (en) * 2006-12-15 2008-06-26 Janssen Pharmaceutica N.V. Benzimidazole TRPV1 inhibitors

Also Published As

Publication number Publication date
US20110190344A1 (en) 2011-08-04
US20110190364A1 (en) 2011-08-04
UA94749C2 (en) 2011-06-10
RS51473B (en) 2011-04-30
KR101434883B1 (ko) 2014-08-27
UY30322A1 (es) 2007-08-31
SI2021330T1 (sl) 2011-01-31
CA2651128A1 (en) 2007-11-15
PT2021330E (pt) 2010-12-03
NO341965B1 (no) 2018-03-05
AU2007248341B2 (en) 2011-12-08
JO3602B1 (ar) 2020-07-05
CN101511797A (zh) 2009-08-19
DE602007009378D1 (de) 2010-11-04
HK1131971A1 (en) 2010-02-12
WO2007130780A3 (en) 2008-02-14
EA019386B1 (ru) 2014-03-31
EA200870497A1 (ru) 2009-06-30
KR20090008428A (ko) 2009-01-21
DK2021330T3 (da) 2010-12-06
IL194916A (en) 2013-01-31
EP2021330B1 (en) 2010-09-22
BRPI0709803A2 (pt) 2011-07-26
CN101511797B (zh) 2013-01-02
AR060840A1 (es) 2008-07-16
BRPI0709803B1 (pt) 2019-12-10
MX2008014108A (es) 2008-11-14
JP5302884B2 (ja) 2013-10-02
ES2350959T3 (es) 2011-01-28
NZ572251A (en) 2010-08-27
JP2009535414A (ja) 2009-10-01
ZA200810234B (en) 2010-02-24
US20070259936A1 (en) 2007-11-08
AU2007248341C1 (en) 2013-01-17
EP2021330A2 (en) 2009-02-11
PL2021330T3 (pl) 2011-03-31
CA2651128C (en) 2014-09-02
BRPI0709803B8 (pt) 2021-05-25
US7951829B2 (en) 2011-05-31
ATE482201T1 (de) 2010-10-15
ECSP088854A (es) 2008-11-27
CR10479A (es) 2009-03-31
MY154595A (en) 2015-06-30
TW200808738A (en) 2008-02-16
WO2007130780A2 (en) 2007-11-15
HRP20100700T1 (hr) 2011-02-28
NO20085031L (no) 2009-01-06
AU2007248341A1 (en) 2007-11-15
CO6160329A2 (es) 2010-05-20
TWI419882B (zh) 2013-12-21
PE20080065A1 (es) 2008-02-25
CY1111269T1 (el) 2015-08-05
IL194916A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
UY30322A1 (es) Moduladores bencimidazólicos de vr1
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CR10213A (es) Moduladores de la proteína quinasa aurora
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
EA201100037A1 (ru) Органические соединения
GT200600327A (es) Ciclohexilaminoisoquinolona
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
EA201170772A1 (ru) Органические соединения
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
EA200970156A1 (ru) Пиридизиноновые производные
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
UY31065A1 (es) Heterociclos ciclicos
GT200600117A (es) Nuevos compuestos farmaceuticos
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
HRP20090076A2 (en) Antiviral phosphinate compounds
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
EA201171488A1 (ru) Lxr модуляторы